Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

While the bears dominated price action early last week, the bulls managed to show strong support below $100,000. Bitcoin price dropped briefly below $100,000 on Tuesday, Wednesday, and Friday, but ...

Eleanor has an undergraduate degree in zoology from the University of Reading and a master’s in wildlife documentary production from the University of Salford. Eleanor has an undergraduate degree in ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

The biotech uses one of the world’s largest datasets and AI supercomputers to find new drugs, but continued losses and lack of commercial products keep risk levels high. Recursion Pharmaceuticals is a ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, marking a +2.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.54% ...